ReS13-I program (reMYND)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameReS13-I program (reMYND)
Drug Alias NameReSX-i program (reMYND)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgium
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRemynd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRemynd
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A